Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor

Inclusion criteria

• 18 years of age and older
• ECOG ≤2
• Pathologically confirmed locally advanced or metastatic well-differentiated pancreatic neuroendocrine tumor.
• Prior treatment with one-line chemotherapy is allowed, with the exception of prior treatment with temozolomide or dacarbazine or endostatin within the past 6 months
• Disease progressed during or after last therapy
• Minimum of 4 weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy
• Disease progressed within the past 12 months。
• Patients must have at least one measurable site of disease according to RECIST1.1 criteria that has not been previously irradiated.
• Adequate bone marrow, liver and renal function
• Life expectancy 3 months or more
• Patient informed consent。

Exclusion criteria

• Concurrent use of Octreotide or other drug that may have efficacy in neuroendocrine tumor.
• 2 or more lines of prior chemotherapy。
• Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
• Uncontrolled infectious disease。
• Other malignancies within the past 5 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinoma of the skin
• Uncontrolled brain or leptomeningeal metastases
• Patients with known hypersensitivity to temozolomide or endostatin。
• Patient could not take tablets。